Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Jt Dis Relat Surg ; 35(2): 361-367, 2024 Mar 21.
Article in English | MEDLINE | ID: mdl-38727116

ABSTRACT

OBJECTIVES: This study aims to compare the radiological, biomechanical, and histopathological results of microfracture treatment and osteochondral damage repair treatment with a new scaffold product produced by the three-dimensional (3D) bioprinting method containing gelatin-hyaluronic acid-alginate in rabbits with osteochondral damage. MATERIALS AND METHODS: A new 3D bioprinted scaffold consisting of gelatin, hyaluronic acid, and alginate designed by us was implanted into the osteochondral defect created in the femoral trochlea of 10 rabbits. By randomization, it was determined which side of 10 rabbits would be repaired with a 3D bioprinted scaffold, and microfracture treatment was applied to the other knees of the rabbits. After six months of follow-up, the rabbits were sacrificed. The results of both treatment groups were compared radiologically, biomechanically, and histopathologically. RESULTS: None of the rabbits experienced any complications. The magnetic resonance imaging evaluation showed that all osteochondral defect areas were integrated with healthy cartilage in both groups. There was no significant difference between the groups in the biomechanical load test (p=0.579). No statistically significant difference was detected in the histological examination using the modified Wakitani scores (p=0.731). CONCLUSION: Our study results showed that 3D bioprinted scaffolds exhibited comparable radiological, biomechanical, and histological properties to the conventional microfracture technique for osteochondral defect treatment.


Subject(s)
Alginates , Bioprinting , Cartilage, Articular , Gelatin , Hyaluronic Acid , Knee Joint , Printing, Three-Dimensional , Tissue Scaffolds , Animals , Rabbits , Alginates/chemistry , Gelatin/chemistry , Hyaluronic Acid/chemistry , Hyaluronic Acid/therapeutic use , Tissue Scaffolds/chemistry , Cartilage, Articular/pathology , Cartilage, Articular/injuries , Cartilage, Articular/surgery , Knee Joint/surgery , Knee Joint/pathology , Bioprinting/methods , Disease Models, Animal , Biomechanical Phenomena , Magnetic Resonance Imaging , Arthroplasty, Subchondral/methods
2.
Minerva Anestesiol ; 90(1-2): 22-30, 2024.
Article in English | MEDLINE | ID: mdl-37997303

ABSTRACT

BACKGROUND: This study aims to reveal the perioperative analgesic efficacy of a new technique, anterior capsular shoulder block, in treating pain after shoulder arthroscopy compared to the interscalene brachial plexus block. METHODS: The study design is randomized, prospective, interventional, standardized and double-blind in the setting of orthopedic operating room and orthopedic postoperative ward. Forty patients between 18-90 years of age and with American Society of Anesthesiologists Physical Status classification I to III who received arthroscopic cuff repair surgery were randomized into two (1:1 distribution; N.=20) groups. The interventions were interscalene brachial plexus block for Group A and shoulder anterior capsular block for Group B. Primary measurements were pain scores within 48 hours. Secondarily total analgesia requirement, intraoperative heart rate and blood pressure, arthroscopic image quality were evaluated. RESULTS: Pain scores within postoperative 48 hours were similar between SHAC and ISB groups with no significant difference (P>0.05). Total analgesia requirement, intraoperative and postoperative rescue analgesia, was also similar with no significance (P>0.05). CONCLUSIONS: This study demonstrated that the anterior capsular shoulder block is an effective alternative with similar results to the interscalene brachial plexus block for managing pain after shoulder arthroscopy.


Subject(s)
Brachial Plexus Block , Shoulder , Humans , Anesthetics, Local , Arthroscopy , Brachial Plexus Block/methods , Pain, Postoperative/drug therapy , Pain, Postoperative/prevention & control , Prospective Studies , Double-Blind Method
3.
Ulus Travma Acil Cerrahi Derg ; 28(11): 1627-1633, 2022 Nov.
Article in English | MEDLINE | ID: mdl-36282170

ABSTRACT

BACKGROUND: Tranexamic acid (TXA) has been shown to reduce intraoperative bleeding and the need for post-operative allogenic blood transfusion requirement in surgery. In our randomized controlled study, we aimed to evaluate the effect of pre-operative 15 mg/kg intravenous TXA on total blood loss (TBL), hidden blood loss (HBL), and transfusion requirement in elderly patient group with intertrochanteric femoral fracture (ITFF) and treated with proximal femoral nailing (PFN). METHODS: Patients diagnosed with ITFFs (AO types 31-A1 and 31-A2) and treated using closed reduction and PFN was divided into two groups in our prospective randomized study. Group 1 (TXA group) was administered 15 mg/kg of TXA 15 min before the incision was made, after anesthesia was given, in the form of an IV infusion in 100 cc of saline. Group 2 (control group) was given only 100 cc of isotonic saline. The primary outcome of the study was TBL. The secondary outcomes were the number of transfusions, HBL, and the surgical (intraoperative) blood loss during the operative procedure and post-operative complications. The outcome values were compared between two groups. RESULTS: One hundred and two patients (51 patients in each group) were included in our study. There were no statistically significant differences between the two groups in terms of their demographic characteristics and their pre-operative hemoglobin and hematocrit values. The mean TBL was statistically lower in the TXA group than in the control group (684.6±370.1 ml vs. 971.2±505.3 ml, respectively; p=0.002). The amount of intraoperative blood loss was not significantly different between two groups (102.4±59.3 ml in the TXA group vs. 112.7±90.1 ml in the control group, p=0.67). However, the mean estimated HBL was significantly lower in the TXA group than in the control group (582.3±341.2 ml vs. 857.8±493.1 ml, respectively; p=0.002). The post-operative blood transfusion rate and transfusion unit were found to be significantly lower in the TXA group than in the control group (8% vs. 23.5%, respectively [p=0.033], and 6 U vs. 15 U, respectively [p=0.04]). Both medical and surgical post-operative complications were found to be similar for two groups. CONCLUSION: Single dose of TXA significantly reduces TBL, HBL, and the need for blood transfusions following PFN in elderly patients with ITFFs, while it does not increase the risk of DVT or thromboembolic events.


Subject(s)
Antifibrinolytic Agents , Fracture Fixation, Intramedullary , Hip Fractures , Tranexamic Acid , Humans , Aged , Tranexamic Acid/therapeutic use , Antifibrinolytic Agents/therapeutic use , Prospective Studies , Blood Loss, Surgical/prevention & control , Hip Fractures/surgery
SELECTION OF CITATIONS
SEARCH DETAIL
...